awmsg logo



ofatumumab (Arzerra®)


Reference No. 2300

Publication date:
03/04/2017


Appraisal information

ofatumumab (Arzerra®) concentrate for solution for infusion


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ministerial ratification: 03/04/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ofatumumab (Arzerra®) cannot be endorsed for use within NHS Wales in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed chronic lymphocytic leukaemia.
Statement of Advice (SOA)
Download